Asylia Means Immunity!

Asylia Therapeutics is a private development stage biotechnology company committed to transforming scientific advances into safe and effective medicines for cancer and auto-immune diseases.  Founded in 2019 and based in Houston, Texas, the company is led by a seasoned team of entrepreneurs, scientific leaders in immunity, oncology and clinical trials, and biotech executives with experience in antibody drug and business development.

Immunotherapy is making a meaningful impact on clinical outcomes but only a small fraction of patients achieve durable benefits because cancer can become invisible to the body’s immune system. Asylia’s platform centers on a drug pipeline capable of modulating antigen presentation to the immune system which has produced unprecedented anti-tumor responses across multiple cancer models.

The company’s lead product, ASY-77A, is a novel antibody that recognizes the extracellular form of Heat Shock Protein (HSP)-70, created at MD Anderson Cancer Center. ASY-77A works by increasing the ability of dendritic cells, which are key to starting immune reactions, to better recognize the presence of cancer cells. As a result, T-cells become activated to kill cancer cells. ASY-77A has produced complete regression of various cancer types in pre-clinical models including solid tumors such as breast and colon cancer, and blood-related cancers like multiple myeloma.